Avoro Capital Advisors’s Adaptimmune Therapeutics ADAP Stock Holding History

Avoro Capital Advisors’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,024,400	Closed	-$8.62M	–	48
2021 Q2	$8.62M	Sell	2,024,400 -1,525,600	-43%	-$7.4M	0.15%	43
2021 Q1	$18.9M	Hold	3,550,000	–	–	0.33%	36
2020 Q4	$19.1M	Sell	3,550,000 -7,450,000	-68%	-$40.5M	0.33%	33
2020 Q3	$87.8M	Buy	11,000,000 +1,000,000	+10%	+$8.75M	1.25%	16
2020 Q2	$100M	Buy	+10,000,000	New	+$62.8M	1.98%	16
2015 Q3	–	Sell	-183,900	Closed	-$3.37M	–	34
2015 Q2	$3.37M	Buy	+183,900	New	+$3.16M	0.93%	24

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Avoro Capital Advisors's ADAP Position: Q3 2021 in Review

Avoro Capital Advisors sold out of Adaptimmune Therapeutics (ADAP) in Q3 2021, closing a stake of 2,024,400 shares — an estimated $8.62M sold.

Avoro Capital Advisors first reported a position in ADAP in Q2 2015 and held it in 6 quarters. The position peaked at $100M in Q2 2020. 92 funds tracked by Wall St. Rank hold ADAP as of Q3 2021.

Avoro Capital Advisors reported no remaining Adaptimmune Therapeutics position as of Q3 2021 after selling out during the quarter.
Avoro Capital Advisors sold 2,024,400 Adaptimmune Therapeutics shares in Q3 2021, an estimated $8.62M.
Avoro Capital Advisors first reported a position in Adaptimmune Therapeutics in Q2 2015 and held it in 6 quarters.
Avoro Capital Advisors's Adaptimmune Therapeutics position peaked at $100M in Q2 2020.
92 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2021.

Based on Avoro Capital Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.